Predictors of inferior clinical outcome in patients with standard ‐risk multiple myeloma

ConclusionOur analysis suggests that concurrent AL and soft tissue plasmacytoma were associated with shorter PFS and OS, respectively. Heterogeneity in clinical outcome of SR MM merits better tools for prognostication, such as gene expression profiling and minimal residual disease assessment to identify high‐risk patients.
Source: European Journal of Haematology - Category: Hematology Authors: Tags: Original Article Source Type: research

Related Links:

INTRODUCTION: Despite advances in therapy, patients with relapsed AL amyloidosis die of resistant disease. New therapies are needed. siRNA directed at the constant regions of Ig light chains (LC) reduces LC mRNA and protein from patient cells, from human myeloma and AL cell lines, and in a flank plasmacytoma model with in vivo electroporation (Blood 2014;123:3440; Gene Ther 2016;23:727). To deliver siRNA in vivo, we first tested a series of biodegradable lipidoid nanoparticles (LPN) generated through Michael addition of aliphatic acrylates containing disulfide bonds responsive to intracellular glutathione that enhance siRN...
Source: Blood - Category: Hematology Authors: Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Source Type: research
Conclusion:This is the first report on the management of MM patients in UAE. With a median follow-up of 216 days (range 3 to 839 days) the response rate to induction therapy was 72% (CR+ VGPR). We are unable to report progression free survival due to short follow-up. This response rate of 72% (VGPR or better) is less than the reported in the literature. This may partly be due to lack of patient data regarding induction therapy elsewhere, the use of double over triplet regimens and the absence of autoSCT facilities. Outcome measurement is a difficult task due to tendency of local citizens to travel outside UAE for treatment...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation Source Type: research
Plasma cell neoplasms (PCNs) are characterized by the uncontrolled clonal expansion of genetically altered plasma cells. These diseases include the precursor lesion monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, plasma cell myeloma (or multiple myeloma), plasmacytoma, monoclonal immunoglobulin deposition diseases (amyloidosis), and PCNs associated with paraneoplastic syndromes. While karyotype and fluorescence in situ hybridization (FISH) analyses have been instrumental in determining prognosis and guiding therapy, the clinical significance of new and emerging molecular markers raise the nee...
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Tags: Review Article Source Type: research
Authors: Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R Abstract Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hyperca...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
ConclusionOur analysis suggests that concurrent AL and soft‐tissue plasmacytoma were associated with shorter PFS and OS, respectively. Heterogeneity in clinical outcome of SR MM merits better tools for prognostication, such as gene expression profiling and minimal residual disease assessment to identify high‐risk patients.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Tags: Original Article Source Type: research
Multiple myeloma is a malignancy of the plasma cell usually associated with a monoclonal gammopathy, most commonly IgG and IgA.1 While the classic symptoms of multiple myeloma are related to hypercalcemia, renal failure, anemia, and bone disease,1,2 multiple myeloma may also be associated with cutaneous findings, including direct infiltration of malignant cells into the skin presenting as cutaneous plasmacytoma,3 deposition of paraproteins leading to nasal and facial spicules,4 leukocytoclastic vasculitis,5 cryoglobulinemia, amyloidosis, xanthomas,6 hemangiomas, hyperpigmentation and hypertrichosis as seen in POEMS syndrom...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Abstract Conventional radiographic skeletal survey has been for many years the gold standard to detect the occurrence of osteolytic lesions in patients with multiple myeloma (MM). However, the introduction of more sensitive imaging procedures has resulted in an updated anatomic and functional Durie and Salmon “plus” staging system and has remarkably changed the diagnostic and prognostic approach to this tumor. It is now established that 18fluorine-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) combined with low-dose computed tomography (CT), shortly designated PET/CT, exhibits a ...
Source: Clinical and Experimental Medicine - Category: Research Source Type: research
Conditions:   Hematopoietic/Lymphoid Cancer;   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leuke...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Ac...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Amyloidosis | Genetics | Hematology | Myeloma | Plasmacytoma | Stem Cell Therapy | Stem Cells | Transplants